Global Liquid Biopsy Market Is Expanding Owing To The Increasing Research And Developmental Activities And Growing Demand For Non-Invasive Disease Diagnosis

 

Liquid Biopsy

Overview:

Liquid Biopsy is a diagnostic tool for early detection of cancer. It is also used for monitoring patient response to treatment. Liquid biopsy has received high hopes and expectations from investors. This technology has the potential to revolutionize the field of early cancer detection and provide patients with better outcomes. The ability to detect a cancer biomarker is crucial for reliable results. Once this is achieved, the technology can be applied to improve cancer prevention, treatment, and the quality of life for survivors. The ability to find and treat cancer at an early stage can save countless lives. A liquid biopsy test can help determine if the patient is a good candidate for targeted therapy. Liquid biopsy tests can identify circulating tumor cells (CTCs) as well as exosomes. These are released by tumor cells and can help doctors identify and monitor cancer cells. The test also assesses the genetic makeup of a tumor. Changes in the genome can be used to predict the risk of cancer, which can be helpful in treatment planning.

Market Dynamics:

Growing product launches is estimated to augment growth of the global Liquid Biopsy Market during the forecast period. For instance, NeXT Liquid Biopsy was launched by Personalis, Inc., in September 2020. This is a high-performance, tumor-profiling platform that uses blood samples from tumor patients in advanced stages. Moreover, increasing lack of specificity and sensitivity of liquid biopsy tests is anticipated to restrain growth of the global liquid biopsy market during the forecast period.

Impact of COVID-19: 

COVID-19 was transmitted to several nations globally, and the number of people infected by the virus were increasing daily. This caused immense stress on many government authorities and led to imposition of strict regulations in many regions, for preventing the transmission of the disease. The healthcare sector was also under a lot of stress, as they were not prepared for this outbreak. During this time, COVID-19 patients were prioritized by doctors and this affected the treatments of other diseases. Many other treatments and diagnosis were either delayed or cancelled, as hospitals were running on full capacity. This had a negative impact on the growth of the global liquid biopsy market.

 Key Takeaways:

The global Liquid Biopsy Market is estimated to witness robust growth, exhibiting CAGR of XX% during the forecast period, owing to increasing acquisitions. For instance, Bio-Techne Company acquired Asuragen, Inc., in April 2021. This acquisition will help in the global expansion of  Bio-Techne.

North America region has witnessed significant growth in the global liquid biopsy market over the forecast period, due to increasing investments and rising presence of biotechnology companies.

Key players active in the global Liquid Biopsy Market are CareDx Inc., MDxHealth, GUARDANT HEALTH, Eurofins Scientific INC, Bio-Rad Laboratories, Inc., Exact Sciences Corporation, Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Trovagene, Immucor, Inc., RainDance Technologies Inc., Natera, Inc., MDxHealth, Biocept, Inc., QIAGEN, Menarini Silicon Biosystems and Genomic Health.

Comments

Popular posts from this blog

Security Robot Market is Estimated To Witness High Growth Owing To Increasing Demand for Enhanced Surveillance

The Ever-Evolving Landscape of the Scottish Whisky Market during the Forecast Period 2019-2027

The Global Methyl & Ethyl Chloroacetate Market Is Expected To Register A Cagr Of 7.9% In Terms Of Revenue Over The Forecast Period (2019-2027)